These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21770080)

  • 41. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
    Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
    Jacobson JD; Feigal D
    Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
    [No Abstract]   [Full Text] [Related]  

  • 43. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
    Buck ML
    Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
    [No Abstract]   [Full Text] [Related]  

  • 44. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulating off-label drug use--rethinking the role of the FDA.
    Stafford RS
    N Engl J Med; 2008 Apr; 358(14):1427-9. PubMed ID: 18385495
    [No Abstract]   [Full Text] [Related]  

  • 46. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug promotion.
    Kalish RS
    N Engl J Med; 1995 Apr; 332(15):1032; author reply 1033. PubMed ID: 7794341
    [No Abstract]   [Full Text] [Related]  

  • 48. The Food and Drug Administration's role in promoting consistent labels for generic drugs.
    Duke JD; Kesselheim AS
    JAMA Intern Med; 2014 Aug; 174(8):1213-4. PubMed ID: 24957047
    [No Abstract]   [Full Text] [Related]  

  • 49. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 50. Vioxx may go back on sale after scraping past FDA panel.
    Wadman M
    Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
    [No Abstract]   [Full Text] [Related]  

  • 51. FDA puts forth proposal to mandate patient information.
    Wechsler J
    Formulary; 1995 Oct; 30(10):622-3. PubMed ID: 10151725
    [No Abstract]   [Full Text] [Related]  

  • 52. US FDA calls for technological attack on drug counterfeiting.
    Ault A
    Lancet; 2004 Feb; 363(9410):714. PubMed ID: 15005089
    [No Abstract]   [Full Text] [Related]  

  • 53. Safety-related drug labeling changes approved by FDA.
    White GG
    J Toxicol Clin Toxicol; 1998; 36(3):265-7. PubMed ID: 9678979
    [No Abstract]   [Full Text] [Related]  

  • 54. Which prescription for the illegible and unreadable DTC (direct-to-consumer) brief summary--major surgery or euthanasia?
    Hochhauser M
    Manag Care Q; 2002; 10(3):6-10. PubMed ID: 12476659
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New pediatric dosage rules: information and testing.
    Feeg VD
    Pediatr Nurs; 1998; 24(6):518, 613. PubMed ID: 10085992
    [No Abstract]   [Full Text] [Related]  

  • 56. Drug safety in the digital age.
    Hwang TJ; Bourgeois FT; Seeger JD
    N Engl J Med; 2014 Jun; 370(26):2460-2. PubMed ID: 24963564
    [No Abstract]   [Full Text] [Related]  

  • 57. HL7 Structured Product Labeling - electronic prescribing information for provider order entry decision support.
    Schadow G
    AMIA Annu Symp Proc; 2005; 2005():1108. PubMed ID: 16779395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Off-label drug use.
    Dooley AG
    Med Health R I; 2007 Feb; 90(2):63-5. PubMed ID: 17500258
    [No Abstract]   [Full Text] [Related]  

  • 59. Proposed NSAID package insert labeling.
    Food and Drug Administration U.S. Public Health Service
    J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Information on marketed drugs for doctors and patients. Experience in six European countries.
    Brown P; Charlish P; Brazier H; Butterfield M
    Int J Technol Assess Health Care; 1995; 11(3):410-6. PubMed ID: 7591543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.